Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
Skepta and PUMA Launch Groundbreaking Collection 
Burger King’s Largest Franchisee Carrols, Acquired by RBI for $1 Billion, $500M Revamp 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
Skechers Sales Surge as Growth Lags for Nike and Adidas; Nike Eyes 2024 Olympics 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
PUMA Welcomes AC Milan Star Theo Hernández to the Family 
McDonald's China Faces Backlash for Food Hygiene Violations 
Green industry yes, conservation no: a budget for people, not for nature 
Shanghai's Data Policy Shift Could Propel Tesla's Local Data Center Efforts 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
SAN DIEGO, Feb. 11, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its fourth quarter and full year 2015 financial and operating results after the close of U.S. financial markets on Thursday, February 18, 2016. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | February 18, 2016 |
| Time: | 4:30 pm Eastern Standard Time (1:30 pm Pacific Standard Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 44255837 |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. TRACON’s pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
